drugset / Trial / NCT00041717

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT00041717

Phase 3 Completed 213 enrolled Acorda Therapeutics
RandomizedParallel-groupDouble-blindTreatment

Summary

Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. In people with spinal cord injury, some fibers may be destroyed at the site of injury, while others remain connected but do not work correctly to carry electrical impulses. As a result, subjects with an incomplete spinal cord injury may have spasticity which is muscle spasms or muscle stiffness that makes movement difficult. Fampridine-SR is an experimental drug that increases the ability of the nerve to conduct electrical impulses. This study will examine the effects of Fampridine-SR on moderate to severe lower-limb spasticity, as well as the effects on bodily functions such as bladder control, bowel function and sexual function. The study will also examine the possible risks of taking Fampridine-SR.

Timeline

Start
2002-07
Primary completion
2004-02
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dalfampridine Small molecule 25 mg Oral

Indications